MODEL SPOTLIGHT | LL/2 – An Immunosuppressive Murine Tumor Model

The advent of immunotherapy has necessitated syngeneic mouse tumor models to further advance the development of immuno-oncology treatments. One of these models is the LL/2 (Lewis Lung) lung carcinoma model that has been characterized to support development of novel agents and approaches to the treatment of “cold,” non-immunogenic tumors.

In this model spotlight our share LL/2 data regarding:

  • Tumor Immune Profile
  • Growth and Response to Doxorubicin and Paclitaxel Therapy
  • Response to Checkpoint Inhibitors anti-mPD-1 and anti-mPD-L1
  • Combination Treatment with Checkpoint Inhibitors and Paclitaxel
  • Combination Treatment with Localized Radiation and anti-mPD-1

Discover the specifics around our LL/2 data and what this tumor model can support when conducting a preclinical immuno-oncology lung carcinoma study.

Download the PDF instantly by filling out the form on this page.